Abstract:Tumor cells in bone can induce the activation of osteoclasts, which mediate bone resorption and release of growth factors and calcium from the bone matrix, resulting in a cycle of tumor growth and bone breakdown. Targeting the bone microenvironment by the inhibition of RANKL, an essential mediator of osteoclast function, not only prevents tumor-induced osteolysis but also decreases skeletal tumor burden in preclinical models. The inhibition of skeletal tumor progression after the inhibition of osteoclasts is via interruption of the “vicious cycle” of tumor/bone interactions. The majority of breast cancer patients at risk for bone metastases harbor estrogen receptor-positive (ER+) tumors. We developed a mouse model for ER+ breast cancer bone metastasis and evaluated the effect of RANKL inhibition on tumor-induced osteolysis and skeletal tumor growth both alone and in combination with tamoxifen. Luciferase-labeled MCF-7 cells (MCF-7Luc) formed metastatic foci in the hind limbs following intracardiac injection and caused mixed osteolytic/osteoblastic lesions. RANKL inhibition by OPG-Fc treatment blocked osteoclast activity and prevented tumor-induced osteolysis, as well as caused a marked decrease in skeletal tumor burden. Tamoxifen as a single agent reduced MCF-7Luc tumor growth in the hind limbs. In a combination experiment, OPG-Fc plus tamoxifen resulted in significantly greater tumor growth inhibition than either single agent alone. Histologic analysis revealed a decrease in the proliferation of tumor cells by both single agents, which was enhanced in the combination treatment. Upon treatment with OPG-Fc alone or in combination with tamoxifen, there was a complete absence of osteolytic lesions, demonstrating the ability of RANKL inhibition to prevent skeletal related morbidity in an ER+ model. The combination approach of targeting osteoclasts and the bone microenvironment by RANKL inhibition and the tumor directly via hormonal therapy may provide additional benefit to reducing skeletal tumor progression in ER+ breast cancer patients.

Targeting the RANKL/RANK/OPG Axis for Cancer Therapy

Isoalantolactone Inhibits RANKL-induced Osteoclast Formation Via Multiple Signaling Pathways

RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives

Research and Application of Target Therapy for Osteoporosis

Roles of the RANKL–RANK Axis in Immunity—Implications for Pathogenesis and Treatment of Bone Metastasis

Targeting RANK/RANKL in the treatment of solid tumours and myeloma

The Roadmap of RANKL/RANK Pathway in Cancer

RANKL/RANK System-Based Mechanism for Breast Cancer Bone Metastasis and Related Therapeutic Strategies

The RANK/RANKL/OPG system and tumor bone metastasis: Potential mechanisms and therapeutic strategies

Expression Profile of Receptor Activator of Nuclear-Κb (RANK), RANK Ligand (RANKL) and Osteoprotegerin (OPG) in Breast Cancer.

Discovery of the RANKL/RANK/OPG system

RANKL and RANK as novel therapeutic targets for arthritis

TNF-family member Receptor Activator of NF-κB (RANK) and RANK-Ligand (RANKL) in bone remodelling

Regulation of cancer cell migration and bone metastasis by RANKL

Targeting the RANK/RANKL pathway in autoimmune disease and malignancy: future perspectives

RANK pathway in cancer: underlying resistance and therapeutic approaches

Advances of RANKL/RANK Pathway in Tumorigenesis and Metastasis of Breast Cancer

The Study of Natural Compounds Targeting RANKL Signaling Pathway for the Treatment of Bone Diseases

Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials

RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model

Immunomodulatory Effects of RANK/RANKL Blockade in Patients with Cancer